We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Protein Assays Validated for Autoanalyzer

By LabMedica International staff writers
Posted on 24 Feb 2011
Fourteen human serum protein assays have been developed and validated for fully automated, user-programmable analyzer. More...


The autoanalyzer is designed to perform potentiometric and photometric assays in serum, plasma, urine, and cerebrospinal fluid, as well as various supernatant sample types.

The assays were developed by scientists at the Foundation for Blood Research, (Scarborough, ME, USA), using de-identified, surplus serum samples stored at -20 °C for less than two months. Samples were selected to encompass a broad range of analyte concentrations and were used for the method comparison studies. The 14 human serum proteins assayed were 1-antitrypsin, 2-macroglobulin, albumin, apolipoproteins AI and B, complement components 3 and 4, haptoglobin, immunoglobulins A, G, and M, orosomucoid, transferrin, and transthyretin. The autoanalyzer used was the versatile Roche cobas c 501, (Roche Diagnostics; Indianapolis, IN, USA), which is from their 6000 series.

Immunoturbidimetric assays for 12 of the 14 proteins were developed using monospecific goat antihuman serum from Midland BioProducts Corporation (Boone, IA, USA). For assaying α-1-antitrypsin and α-2-macroglobulin, goat antihuman serum was obtained from International Immunology Corporation (Murrieta, CA, USA) and DiaSorin (Stillwater, MN, USA), respectively.

The scientists obtained excellent precision at low, normal, and high physiologic concentrations of each protein. Linearity for each method was within 5% of the expected value throughout the calibration range, and method comparison studies to commercial assays were in good agreement. No significant interference was observed from bilirubin, up to 414 mg/L, hemoglobin up to 8.9 g/L, triglyceride, up to 28 g/L, or rheumatoid factor, up to 3,930 IU/mL. Calibration was stable for at least 14 days. The instrument's small reaction cell allowed conservation of nearly 60% of the specimen and reagent volume compared with another system.

The scientists concluded that these newly developed assays provide precise and accurate results with high throughput, but without the associated cost of a dedicated instrument. The study was published on January 19, 2011, in the Journal of Clinical Laboratory Analysis.

Related Links:

Foundation for Blood Research
Roche Diagnostics
Midland BioProducts Corporation
International Immunology Corporation
DiaSorin



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.